ATE481134T1 - Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen - Google Patents

Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen

Info

Publication number
ATE481134T1
ATE481134T1 AT05705915T AT05705915T ATE481134T1 AT E481134 T1 ATE481134 T1 AT E481134T1 AT 05705915 T AT05705915 T AT 05705915T AT 05705915 T AT05705915 T AT 05705915T AT E481134 T1 ATE481134 T1 AT E481134T1
Authority
AT
Austria
Prior art keywords
tyrosine kinase
kinase inhibitors
compositions
treatment
pathogenic infections
Prior art date
Application number
AT05705915T
Other languages
English (en)
Inventor
Daniel Kalman
William Bornmann
Melanie Sherman
Patrick Reeves
Alyson Swimm
Original Assignee
Univ Emory
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Sloan Kettering Inst Cancer filed Critical Univ Emory
Application granted granted Critical
Publication of ATE481134T1 publication Critical patent/ATE481134T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05705915T 2004-01-21 2005-01-20 Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen ATE481134T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53796004P 2004-01-21 2004-01-21
US55368104P 2004-03-16 2004-03-16
US61420304P 2004-09-29 2004-09-29
PCT/US2005/001710 WO2005072826A2 (en) 2004-01-21 2005-01-20 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection

Publications (1)

Publication Number Publication Date
ATE481134T1 true ATE481134T1 (de) 2010-10-15

Family

ID=34831196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05705915T ATE481134T1 (de) 2004-01-21 2005-01-20 Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen

Country Status (8)

Country Link
US (1) US8765777B2 (de)
EP (3) EP2260849A1 (de)
JP (2) JP5520433B2 (de)
AT (1) ATE481134T1 (de)
AU (1) AU2005209231B8 (de)
CA (1) CA2554201C (de)
DE (1) DE602005023587D1 (de)
WO (1) WO2005072826A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554201C (en) 2004-01-21 2015-04-14 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
JP5015769B2 (ja) * 2004-06-04 2012-08-29 バイオニケ ライフ サイエンシーズ インコーポレイテッド 肝臓疾患及びウイルス感染を治療するためのイマチニブの使用
WO2006017353A2 (en) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES, as represented byTHE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of viral infections
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
WO2007002441A1 (en) * 2005-06-24 2007-01-04 Emory University Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection
ATE417274T1 (de) * 2006-06-01 2008-12-15 Cellzome Ag Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung
EP2063882A4 (de) * 2006-09-05 2010-03-03 Univ Emory Tyrosinkinasehemmer zur vorbeugung oder behandlung von infektionen
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
WO2008151183A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
JP5559043B2 (ja) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
JP5710251B2 (ja) * 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規ヘテロ環化合物およびその使用
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication
ES2650630T3 (es) 2011-10-03 2018-01-19 The University Of North Carolina At Chapel Hill Compuestos de pirrolopirimidina para el tratamiento del cáncer
EP2852579A4 (de) 2012-05-22 2015-12-30 Univ North Carolina Pyrimidinverbindungen zur krebsbehandlung
CA2886744A1 (en) 2012-10-04 2014-04-10 Inhibikase Therapeutics, Inc. Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (de) 2012-11-27 2016-06-01 Univ North Carolina Pyrimidinverbindungen zur krebsbehandlung
EP2769722A1 (de) * 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Verbindungen zur Verwendung bei der Hemmung einer HIV-Kapsid-Anordnung
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP2905024A1 (de) * 2014-02-07 2015-08-12 Institut Quimic De Sarriá Cets, Fundació Privada Pyrido[2,3-d]pyrimidin-7(8H)-on-Derivate zur Behandlung von Flaviviridae Infectionen
WO2015157128A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
WO2017049036A1 (en) * 2015-09-16 2017-03-23 Emory University Use of kinase inhibitors to manage tuberculosis and other infectious diseases
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
JOP20210305A1 (ar) 2019-05-16 2023-01-30 Aerovate Therapeutics Inc صيغ إيماتينيب وتصنيعها واستخداماتها
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2021046438A1 (en) * 2019-09-04 2021-03-11 The Regents Of The University Of California Regenerating functions and phenotypes of connective tissue through npas2 suppression
CN111925368B (zh) * 2020-07-04 2021-11-05 中国医学科学院医药生物技术研究所 嘧啶酮类衍生物及其制备方法和在抗结核杆菌感染中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
US3439089A (en) 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US4439089A (en) 1978-10-12 1984-03-27 Dresser Industries, Inc. Boom arm with rock deflection feature
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
MD1861G2 (ro) 1994-11-14 2002-09-30 Уорнер-Ламберт Кампэни Derivaţi ai 6-arilpirido[2,3-d]pirimidinelor şi naftiridinelor, compoziţie farmaceutică pe baza lor, metode de tratament şi de inhibare a proliferării şi migraţiei celulei receptorului tirozinkinazei
EP1073435B1 (de) 1998-04-30 2004-07-07 Abbott GmbH & Co. KG Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
JP3989175B2 (ja) 1999-04-15 2007-10-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
ES2383763T3 (es) * 1999-12-22 2012-06-26 The Scripps Research Institute Composiciones farmacéuticas que comprenden Src y/o Yes y su utilización
JP2004520007A (ja) * 2000-08-01 2004-07-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｋｓｈｖ感染の遺伝子発現プロフィール及びｋｓｈｖ感染を処置する方法
EP1307450B1 (de) * 2000-08-04 2008-09-17 Warner-Lambert Company LLC 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-one
DE60136731D1 (de) 2000-09-20 2009-01-08 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
EP1201765A3 (de) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Mit Zytomegalovirusinfektion verknüpften zellulären Kinasen und ihre Hemmung
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
MXPA03005777A (es) 2000-12-22 2005-02-14 Johnson & Johnson Derivados de triazol diaminas sustituidos como inhibidores de cinasa.
EP1450775B1 (de) * 2001-09-20 2008-03-12 AB Science C-kithemmer zur behandlung von bakteriellen infektionen
GB0125659D0 (en) 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
FR2844452A1 (fr) 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7384907B2 (en) 2002-12-13 2008-06-10 Duke University Method of treating infection with ABl tyrosine kinase inhibitors
EP1613736A4 (de) * 2003-03-11 2007-04-11 Dana Farber Cancer Inst Inc Hemmung der viruspathogenese
CA2554201C (en) 2004-01-21 2015-04-14 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
JP5015769B2 (ja) * 2004-06-04 2012-08-29 バイオニケ ライフ サイエンシーズ インコーポレイテッド 肝臓疾患及びウイルス感染を治療するためのイマチニブの使用
WO2007002441A1 (en) 2005-06-24 2007-01-04 Emory University Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection
EP2063882A4 (de) 2006-09-05 2010-03-03 Univ Emory Tyrosinkinasehemmer zur vorbeugung oder behandlung von infektionen

Also Published As

Publication number Publication date
EP2260849A1 (de) 2010-12-15
WO2005072826A2 (en) 2005-08-11
WO2005072826A3 (en) 2006-04-20
AU2005209231B2 (en) 2011-03-17
JP2010202674A (ja) 2010-09-16
EP1725295B1 (de) 2010-09-15
CA2554201C (en) 2015-04-14
JP2007518810A (ja) 2007-07-12
US8765777B2 (en) 2014-07-01
AU2005209231A1 (en) 2005-08-11
AU2005209231B8 (en) 2011-07-28
DE602005023587D1 (de) 2010-10-28
US20110281867A1 (en) 2011-11-17
EP1725295A2 (de) 2006-11-29
EP2233174A1 (de) 2010-09-29
JP5520433B2 (ja) 2014-06-11
CA2554201A1 (en) 2005-08-11
EP2233174B1 (de) 2016-07-20

Similar Documents

Publication Publication Date Title
ATE481134T1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
ATE419859T1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
DE60309701D1 (de) 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
HK1137366A1 (en) Pharmaceutical compositions comprising activin-actriia antagonists and use thereof in preventing or treating multiple myeloma
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
NO20082862L (no) Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
EA201100874A1 (ru) Соединения для лечения рака
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
EA200702583A1 (ru) Использование фенилсемикарбазонов для обработки семян
ATE555108T1 (de) Polyamide zur behandlung des menschlichen papilloma-virus
ATE445644T1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
ATE548044T1 (de) Kombinationstherapie zur behandlung von hiv- infektionen
DE602005018366D1 (de) Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
DE602004022689D1 (de) Verwendung probiotischer bakterien zur behandlung von infektionen
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
WO2010052575A3 (en) Ngna compositions and methods of use
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties